Statin-dye conjugates for selective targeting of KRAS mutant cancer cells.

Abstract excerpt

Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statin-based conjugates could achieve selective uptake specifically in KRASMUT cells. To investigate this, we...

Topics

Join the communities discussing this publication.

• Pravastatin
• Carbocyanines
• Carcinoma, Pancreatic Ductal
• Coculture Techniques
• Fluorescent Dyes